163 related articles for article (PubMed ID: 24187755)
1. [Stem cells: scientific progress and commercial tactics].
Nau JY
Rev Med Suisse; 2013 Oct; 9(400):1794-5. PubMed ID: 24187755
[No Abstract] [Full Text] [Related]
2. Advances in cell lineage reprogramming.
Zhou J; Yue W; Pei X
Sci China Life Sci; 2013 Mar; 56(3):228-33. PubMed ID: 23526388
[TBL] [Abstract][Full Text] [Related]
3. Why regenerative stem cell medicine progresses slower than expected.
Rosemann A
J Cell Biochem; 2014 Dec; 115(12):2073-6. PubMed ID: 25079695
[No Abstract] [Full Text] [Related]
4. [Ethical reflections on cell reprogramming].
Aznar Lucea J; Martínez M
Cuad Bioet; 2012; 23(78):287-99. PubMed ID: 23130744
[TBL] [Abstract][Full Text] [Related]
5. Human stem cell research and regenerative medicine--present and future.
Volarevic V; Ljujic B; Stojkovic P; Lukic A; Arsenijevic N; Stojkovic M
Br Med Bull; 2011; 99():155-68. PubMed ID: 21669982
[TBL] [Abstract][Full Text] [Related]
6. State stem cell agency floats idea of $70 million 'Alpha' clinics.
Dolgin E
Nat Med; 2013 Jul; 19(7):798. PubMed ID: 23836206
[No Abstract] [Full Text] [Related]
7. REGENERATIVE MEDICINE. California stem cell agency plots a race to the clinic.
Servick K
Science; 2016 Jan; 351(6268):15. PubMed ID: 26721984
[No Abstract] [Full Text] [Related]
8. Somatic cell reprogramming for regenerative medicine: SCNT vs. iPS cells.
Pan G; Wang T; Yao H; Pei D
Bioessays; 2012 Jun; 34(6):472-6. PubMed ID: 22419173
[TBL] [Abstract][Full Text] [Related]
9. Stem cells on the ballot.
Goldstein LSB; Klein RN
Science; 2021 Jan; 371(6526):215. PubMed ID: 33446531
[No Abstract] [Full Text] [Related]
10. The ethics of stem cells revisited.
de Miguel-Beriain I
Adv Drug Deliv Rev; 2015 Mar; 82-83():176-80. PubMed ID: 25446134
[TBL] [Abstract][Full Text] [Related]
11. Induced pluripotent stem cells: an emerging theranostics platform.
Nelson TJ; Terzic A
Clin Pharmacol Ther; 2011 May; 89(5):648-50. PubMed ID: 21512525
[TBL] [Abstract][Full Text] [Related]
12. Cell reprogramming: expectations and challenges for chemistry in stem cell biology and regenerative medicine.
Anastasia L; Pelissero G; Venerando B; Tettamanti G
Cell Death Differ; 2010 Aug; 17(8):1230-7. PubMed ID: 20168332
[TBL] [Abstract][Full Text] [Related]
13. Will cell reprogramming resolve the embryonic stem cell controversy? A narrative review.
Power C; Rasko JE
Ann Intern Med; 2011 Jul; 155(2):114-21. PubMed ID: 21768585
[TBL] [Abstract][Full Text] [Related]
14. The inherent ethical challenge of first-in-human pluripotent stem cell trials.
Habets MG; van Delden JJ; Bredenoord AL
Regen Med; 2014 Jan; 9(1):1-3. PubMed ID: 24350999
[No Abstract] [Full Text] [Related]
15. The NIH and the regenerative medicine field.
Rao M
Regen Med; 2012 Mar; 7(2):129-31. PubMed ID: 22397601
[No Abstract] [Full Text] [Related]
16. Global update: Germany.
Lauter FR; Wirsching S
Regen Med; 2011 Nov; 6(6 Suppl):154-7. PubMed ID: 21999280
[TBL] [Abstract][Full Text] [Related]
17. Welcome to the World Stem Cell Report.
Siegel B
Regen Med; 2011 Nov; 6(6 Suppl):1-2. PubMed ID: 21999254
[No Abstract] [Full Text] [Related]
18. California: 'the Stem Cell State'. Interview with Jonathan Thomas.
Thomas J
Regen Med; 2011 Nov; 6(6 Suppl):113-5. PubMed ID: 21999272
[TBL] [Abstract][Full Text] [Related]
19. A new paradigm for funding medical research.
Klein R
Stem Cells; 2012 Mar; 30(3):360-2. PubMed ID: 22334458
[No Abstract] [Full Text] [Related]
20. Stem cell research in Latin America: update, challenges and opportunities in a priority research area.
Palma V; Pitossi FJ; Rehen SK; Touriño C; Velasco I
Regen Med; 2015; 10(6):785-98. PubMed ID: 26440367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
